已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial

医学 来那度胺 内科学 淋巴瘤 肿瘤科 临床研究阶段 弥漫性大B细胞淋巴瘤 胃肠病学 临床试验 沙利度胺 进行性疾病 相(物质) 多发性骨髓瘤
作者
Georg Lenz,Marek Trněný,John M. Burke,Grzegorz S. Nowakowski,Christopher Paul Fox,Annalisa Chiappella,Johannes Duell,Young Woo Jeon,Chan Yoon Cheah,Jason R. Westin,Joseph Z. Ye,Priscilla Baetiong Caguioa,David Belada,Ho‐Jin Shin,Sung Yong Oh,Sandy Amorim,Matthew Ku,Heidi Móciková,Javier López Jiménez,Gianluca Gaïdano
出处
期刊:The Lancet [Elsevier BV]
卷期号:407 (10547): 2528-2541 被引量:14
标识
DOI:10.1016/s0140-6736(26)00866-4
摘要

Background Approximately 40% of patients with high-risk diffuse large B-cell lymphoma (DLBCL) are not cured with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone). We aimed to investigate the addition of tafasitamab (an Fc-enhanced anti-CD19 monoclonal antibody) and lenalidomide to R-CHOP (tafa-len-R-CHOP) in patients with high-risk aggressive B-cell lymphomas. Methods frontMIND is a phase 3, randomised, double-blind, placebo-controlled study conducted at 298 centres in North America, South America, Europe, and the Asia–Pacific region. Patients aged 18–80 years with previously untreated, high-intermediate-risk or high-risk DLBCL or high-grade B-cell lymphoma (HGBL) were randomly allocated (1:1), stratified by International Prognostic Index (IPI) or age-adjusted IPI and geographical region, to receive six 21-day cycles of standard R-CHOP (rituximab 375 mg/m 2 intravenous on day 1, cyclophosphamide 750 mg/m 2 intravenous on day 1, doxorubicin 50 mg/m 2 intravenous on day 1, vincristine 1·4 mg/m 2 [maximum 2 mg] intravenous on day 1, and prednisone or prednisolone 100 mg/day orally on days 1–5); patients in the tafa-len-R-CHOP group additionally received tafasitamab (12 mg/kg intravenous on days 1, 8, and 15) plus lenalidomide (25 mg/day orally on days 1–10), while those in the R-CHOP group received matching placebos. The primary endpoint was investigator-assessed progression-free survival (defined as time from randomisation to disease progression or death from any cause), analysed in the intention-to-treat population; safety was included as a secondary endpoint among all patients who received at least one dose of study treatment. The trial is registered with ClinicalTrials.gov (NCT04824092) and EUDRA-CT (2020-002990-84) and is active but no longer enrolling. Findings Between May 11, 2021, and March 2, 2023, 1229 patients were screened, among whom 899 were randomly allocated: 448 (50%) to the tafa-len-R-CHOP group and 451 (50%) to the R-CHOP group. At the time of primary analysis (median follow-up 35·2 months [95% CI 35·0–35·4]), progression-free survival was improved in the tafa-len-R-CHOP group versus the R-CHOP group (hazard ratio [HR] 0·75 [95% CI 0·59–0·96]; p=0·0194), with 2-year progression-free survival rates of 71·1% (66·3–75·4) with tafa-len-R-CHOP versus 62·9% (57·9–67·5) with R-CHOP. Interim HR for overall survival was 0·85 (0·63–1·14). The overall rate of grade 3 or higher treatment-emergent adverse events was higher with tafa-len-R-CHOP (384 [87%] of 443) than with R-CHOP (340 [76%] of 447). Additionally, a higher rate of fatal treatment-emergent adverse events was observed with tafa-len-R-CHOP (26 [6%]) than with R-CHOP (17 [4%]). However, the number of overall deaths in the study was lower with tafa-len-R-CHOP than with R-CHOP (82 [19%] vs 97 [22%]). Based on disposition data, rates of premature discontinuation of all study drugs were similar in the tafa-len-R-CHOP group (71 [16%] of 443) and R-CHOP group (66 [15%] of 447). Interpretation Progression-free survival was significantly improved with tafa-len-R-CHOP versus R-CHOP; however, the safety profile indicated increases in adverse events, including treatment-emergent adverse events leading to death, with the addition of tafasitamab and lenalidomide. Overall survival data are immature; follow-up is ongoing. Further analyses, including of circulating tumor DNA, will help to assess whether deeper molecular responses are contributing to the progression-free survival benefit observed with tafa-len-R-CHOP. Tafa-len-R-CHOP might represent a potential new first-line treatment for patients with high-risk DLBCL or HGBL. Funding Incyte Corporation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hfhkjh发布了新的文献求助10
刚刚
dfg发布了新的文献求助10
1秒前
2秒前
我爱小葫芦完成签到,获得积分20
2秒前
司新颖发布了新的文献求助10
2秒前
yqzhang完成签到,获得积分10
3秒前
3秒前
4秒前
4秒前
4秒前
小Y完成签到,获得积分10
5秒前
所所的应助被漂亮的保温杯采纳,获得10
6秒前
lucy发布了新的文献求助10
7秒前
王皮皮完成签到,获得积分20
7秒前
7秒前
sandeyuntao发布了新的文献求助10
8秒前
edisonzz发布了新的文献求助10
8秒前
顾矜的应助被77采纳,获得10
9秒前
Clarissa发布了新的文献求助10
9秒前
10秒前
Maestro_S的应助被jacksen采纳,获得10
12秒前
充电宝的应助被风吹麦浪采纳,获得10
12秒前
桐桐的应助被风吹麦浪采纳,获得10
12秒前
Tulip发布了新的文献求助10
13秒前
星辰大海的应助被Arvin采纳,获得10
13秒前
haui完成签到,获得积分10
13秒前
jyy发布了新的文献求助10
15秒前
科研通AI6.2的应助被j736999565采纳,获得10
16秒前
阿王完成签到,获得积分10
17秒前
外向思松完成签到,获得积分10
18秒前
Birk发布了新的文献求助10
18秒前
泡芙完成签到 ,获得积分10
18秒前
19秒前
zdk完成签到 ,获得积分20
20秒前
20秒前
包容耳机发布了新的文献求助30
21秒前
Orange的应助被DARKNESS采纳,获得10
21秒前
酷波er的应助被难过的谷芹采纳,获得10
21秒前
21秒前
你不好你不好完成签到 ,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179129
求助须知:如何正确求助?哪些是违规求助? 9569710
关于积分的说明 21806324
捐赠科研通 7774507
什么是DOI,文献DOI怎么找? 3433008
关于科研通互助平台的介绍 2556912
邀请新用户注册赠送积分活动 2478649